Is Carvolix SA halal to invest in?

According to Musaffa's Shariah screening methodology, Carvolix SA (CVX.PA) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Carvolix SA a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Carvolix SA using these criteria to determine its compliance status.

Can Muslims buy shares of Carvolix SA?

Muslim investors may consider investing in Carvolix SA if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Carvolix SA classified as NOT COVERED?

Musaffa determines the Shariah status of Carvolix SA by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Carvolix SA updated?

The Shariah compliance status of Carvolix SA may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Carvolix SA become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Carvolix SA?

You can check the latest Shariah compliance status of Carvolix SA on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Carvolix SA CVX.PA

€3.08 €0.06 (1.99%) 1D

Last Updated: May 15, 12:00 AM·XPAR

Carvolix SA. Stock Analysis CVX.PA

France Health Care Micro Cap

Carvolix is a medical technologies company in the commercial and clinical stage, which engages in the provision of structural heart disease and brain stroke treatment. The firm is engaged in developing Artificial Intelligence (AI)‑driven autonomous mini‑robots and biomimetic implants for interventional cardiology and stroke treatment. The company operates through the consolidation, Caranx Medical, and Artedrone, and focuses on technologies used in cardiac valve replacement, structural heart interventions, and neurovascular procedures. The company develops systems combining micro‑robotics, artificial intelligence, imaging guidance, and implantable heart devices. Its product portfolio includes the TAVIPILOT software for transcatheter aortic valve implantation (TAVI), structural heart devices such as Kalios and Epygon, the Artus artificial urinary sphincter, and a robotic platform intended for stroke treatment.

Key Statistics of Carvolix SA (CVX.PA)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

€3.02€3.20

Today's Open

€3.02

Volume

24.46K

P/E Ratio (TTM)

52 Week Range

€2.48€5.22

Market Cap

195.43M

Avg. Volume

14.33K

Dividend Yield

Financial Metrics & Statements of Carvolix SA (CVX.PA)

FAQ's for Carvolix SA (CVX.PA)

According to Musaffa’s Shariah screening methodology, Carvolix SA (CVX.PA) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.